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An inﬂammatory syndrome has been previously reported in chronic schizophrenia. The aims of this study
were to investigate: (1) serum levels and leukocyte gene expression of cytokines in patients with ﬁrst-epi-
sode psychosis and controls; and (2) possible causes of abnormal cytokine levels in ﬁrst-episode psychosis,
testing their association with psychosocial stressors, current nicotine and cannabis use, and duration of
antipsychotic treatment. We recruited 24 ﬁrst-episode psychosis patients and 24 healthy controls
matched for age, gender, ethnicity and body mass index. Serum interleukin(IL)-1a, IL-1b, IL-2, IL-4, IL-6,
IL-8, IL-10, Tumour Necrosis Factor- a (TNF-a), Interferon- c (IFN-c), vascular endothelial growth factor
(VEGF), epidermal growth factor (EGF), and monocyte chemotactic protein-1 (MCP-1) were analysed in
all subjects. Leukocyte gene expression analyses were conducted only for those cytokines that were differ-
ent between-groups in the serum analyses. Patients had signiﬁcantly higher serum levels of IL-1a (effect
size d = 0.6, p = 0.03), IL-1b (d = 0.4, p = 0.01), IL-8 (d = 0.6, p = 0.01) and TNF-a (d = 0.7, p = 0.05) and a
trend for higher IL-6 serum levels (d = 0.3, p = 0.09) when compared with controls. Leukocyte m-RNA
levels of IL-1a (d = 0.6, p = 0.04), IL-6 (d = 0.7, p = 0.01) and TNF-a (d = 1.6, p < 0.001), but not IL-1b and
IL-8, were also signiﬁcantly higher in patients. A history of childhood trauma was associated with higher
TNF-a serum levels (p = 0.01), while more recent stressful life-events were associated with higher TNF-a
mRNA levels in leukocytes (p = 0.002). In conclusion, ﬁrst-episode psychosis is characterised by a
pro-inﬂammatory state supported, at least in part, by activation of leukocytes. Past and recent stressors
contribute to this pro-inﬂammatory state.
 2012 Elsevier Inc. Open access under CC BY license.1. Introduction
In the past two decades, several studies have investigated the
relevance of cytokine alterations in the multifactorial pathogenesis
of schizophrenia (Erbagci et al., 2001; Cazzullo et al., 2001; Zhang
et al., 2002; Na and Kim, 2007). A recent meta-analysis of these
studies suggests the presence of an inﬂammatory syndrome in
schizophrenia, with some cytokines mainly present during acute
exacerbations and possibly to be considered as state marker for
acute schizophrenia, such as interleukin (IL)-1b, IL-6 and trans-
forming growth factor- b (TGF-b), and other cytokines remaining
elevated following antipsychotic treatment and possibly to beychiatry & Stress, Psychiatry
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NU, UK. Tel.: + 44 0 20 7848
ndelli).
 license.considered as trait markers, such as IL-12, interferon-c (INF-c)
and tumor necrosis factor-a (TNF-a) (Miller et al., 2011). Cytokine
alterations in patients with chronic schizophrenia may be partly
due to weight gain, metabolic disorders and obesity (Henderson,
2005), long duration of illness, or multiple drug treatment
(Drzyzga et al., 2006). In order to reduce the role of these possible
confounding factors, it is important to study cytokine network
alterations in subjects with a ﬁrst-episode of psychosis. First-epi-
sode psychosis subjects have a short exposure to antipsychotic
drugs, with fewer metabolic effects and immunological changes
associated to these drugs. To date, only few studies have investi-
gated cytokine levels in subjects with ﬁrst-episode psychosis,
reporting higher serum or plasma levels of IL-1b, IL-6, IL-12, INF-
c, TNF- a, TGF- b and soluble IL-2 receptor (Ganguli and Rabin,
1989; Kim et al., 2000, 2002, 2004, 2009; Theodoropoulou et al.,
2001; Crespo-Facorro et al., 2008; Fernandez-Egea et al., 2009;
Song et al., 2009).
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tory cytokines in psychosis could be related to an over-activation
of the Th1 activity (Crespo-Facorro et al., 2008), resulting in an
imbalance in the Th1/Th2 cytokines ratio, with a shift towards
the Th2 system (Schwarz et al., 2001). However, variations in ser-
um or plasma cytokines levels might not directly reﬂect the activ-
ity of peripheral blood immune cells. Indeed, serum and plasma
cytokine levels may partly derive from the vessel walls or from
other lymphoid or non-lymphoid cells, such as hepatocytes or adi-
pocytes (O’Rourke et al., 2006). For these reasons, studying cyto-
kine gene expression in peripheral blood cells might represent a
more reliable method to investigate the speciﬁc activity of immune
cells and their degree of activation. Moreover, leukocytes have
been proposed as a useful peripheral model to study inﬂammatory
processes in the central nervous system (Sullivan et al., 2006). In
fact, their expression proﬁles have shown similarities to those ob-
served in brain cells, especially for genes encoding stress media-
tors, cytokines, hormones, and growth factors (Glatt et al., 2005;
Sullivan et al., 2006).
In order to capture a comprehensive picture of the inﬂamma-
tory pattern in ﬁrst-episode psychosis, we focussed on a wide
range of inﬂammatory markers, including pro-inﬂammatory
cytokines (interleukins IL-1a, IL-1b, IL-2, IL-6, interferon-gamma
(IFN-c), tumor necrosis factor-alpha (TNF-a)), anti-inﬂammatory
cytokines (IL4, IL-10), chemokines (IL-8, monocyte chemotactic
protein-1 (MCP-1)), and grow factors (vascular endothelial growth
factor (VEGF), epidermal growth factor (EGF)). The ﬁrst aim of this
study was to investigate differences between ﬁrst-episode psycho-
sis subjects and healthy volunteers in the serum; cytokines found
to be different in serum were then investigated as leukocyte gene
expression. The second aim of the study was to understand the
possible causes of altered cytokine serum and gene expression lev-
els in ﬁrst-episode psychosis, testing their association with psy-
chosocial stress, current nicotine and cannabis use, and duration
of antipsychotic treatment. Patients and controls were matched
on clinical and socio-demographic variables, including ethnicity
and body mass index (BMI), to reduce potential confounders.Table 1
Intra-assay precision of cytokine array.
Analyte Level 1 Level 2 Level 3
Conc.
(pg/mL)
%CV Conc.
(pg/mL)
%CV Conc.
(pg/mL)
%CV
IL-2 32.0 9.6 187 5.0 506 6.3
IL-4 22.0 10.7 165 9.4 388 4.6
IL-6 2.2 12.9 21 6.1 44 8.7
IL-8 22.0 10.1 292 7.5 1056 7.9
IL-10 18.0 6.3 214 5.5 457 6.7
VEGF 30.0 7.3 317 4.6 721 4.3
IFN 15.0 12.7 274 6.2 1047 3.8
TNF-a 15.7 10.2 233 6.0 768 7.8
IL-1a 4.9 9.7 105 7.7 339 6.7
IL-1b 10.6 8.2 139 6.3 406 6.7
MCP-1 60.0 6.8 297 5.1 512 4.7
EGF 60.0 4.6 173 5.8 339 7.62. Methods
2.1. Subjects
Twenty-four patients (16 males and 8 females; mean age ± -
SEM: 28.1 ± 1.1 years) presenting with a ﬁrst-episode of a func-
tional psychosis were recruited from the South London and
Maudsley (SLAM) NHS Foundation Trust (Mondelli et al.,
2010a,b). Patients with organic psychosis, learning disabilities or
requiring a translator because of lack of English ﬂuency were ex-
cluded from the study. Twenty-four healthy subjects (15 males
and 9 females; mean age: 26.6 ± 0.9 years) were also recruited. Pa-
tients and controls did not signiﬁcantly differ for age (p = 0.3), gen-
der (chi square = 0.09, p = 1.0), ethnicity (p = 0.2) and BMI (p = 0.1).
Two patients reported some physical health issues, one reporting a
diagnosis of sickle cell disease and the second one reporting history
of asthma (not under any speciﬁc medication at time of assess-
ment). The study was approved by the local Ethics Committee
and written informed consent was obtained from all participants.
Validation of clinical diagnosis according to DSM-IV criteria
(American Psychiatric Association, 2000) was obtained using the
Operational Criteria (OPCRIT) (McGufﬁn et al., 1991). Ten patients
had a diagnosis of schizophrenia-like disorder, 9 of affective psy-
chosis and ﬁve of psychotic disorder not otherwise speciﬁed. The
mean duration of antipsychotic treatment was 33.5 ± 7.2 days
(range 0–129 days). Sixteen patients were taking atypical antipsy-
chotics (such as olanzapine and risperidone), 3 haloperidol, and 5were drug naïve. Blood samples were collected in all subjects in
non-fasting conditions using clot activator tubes for serum analysis
and PaxGene tubes for gene expression analysis.
2.2. Stress measurements
We collected information about stressful life events which had
occurred in the previous six months using the Brief Life Events
questionnaire (Brugha and Cragg, 1990), and measured perceived
stress in the previous month using the Perceived Stress Scale (Co-
hen and Williamson, 1988). Information about childhood trauma
were also collected, using a modiﬁed version of the Childhood
Experience of Care and Abuse (CECA) Questionnaire (Bifulco
et al., 2005), including information about loss of parents, separa-
tion from parents for more than 6 months, and physical and sexual
abuse before the age of 17 years.
2.3. Cytokines serum analysis
The serum was separated, aliquoted and stored at 70 C before
use. Biochip array technology was used to perform simultaneous
quantitative detection of multiple analytes from a single patient
sample. The core technology is the Randox Biochip (http://
www.randox.com), a solid-state device containing an array of dis-
crete test regions of immobilised antibodies speciﬁc to different
cytokines and growth factors. A sandwich chemiluminescent
immunoassay was employed for the cytokine array. This cytokine
array measures the following cytokines and growth factors: inter-
leukin (IL)-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, vascular endothelial
growth factor (VEGF), Tumour Necrosis Factor- a (TNF-a), Inter-
feron- c (IFN-c), epidermal growth factor (EGF), monocyte chemo-
tactic protein-1(MCP-1). Intra-assay precision of the cytokine array
is shown in Table 1. Sensitivity of cytokine assay is shown in Table
2.
2.4. Gene expression analysis
Gene expression analyses were conducted only for cytokines
found to be different in the serum when compared between pa-
tients and controls. PaxGene Tubes were collected at the same time
of the serum samples and kept for two hours at room temperature
after blood samples were withdrawn and then stored at 80 C un-
til they were processed. RNA isolation was performed using the
PAXGene Blood RNA Kit (Qiagen S.p.A., Milan, MI, Italy) according
to manufacturer’s protocols. Two micrograms of total RNA were
used for cDNA synthesis and for subsequent gene expression anal-
ysis in Real Time PCR. Quantitative Real-Time PCR was performed
using HOT FIREPol EvaGreen qPCR Mix (Solis BioDyne, Tartu,
Table 2
Sensitivity of cytokine assay.
Analyte Calibration range (pg/mL) Sensitivity (pg/mL)
IL-2 0–3000 4.8
IL-4 0–4000 6.6
IL-6 0–900 1.2
IL-8 0–3000 7.9
IL-10 0–1000 1.8
VEGF 0–3000 14.6
IFN 0–1500 3.5
TNF-a 0–1500 4.4
IL-1a 0–500 0.8
IL-1b 0–500 1.6
MCP-1 0–1500 13.2
EGF 0–900 2.9
Table 3
Cytokines serum levels and cytokine gene expression in patients with ﬁrst-episode
psychosis and controls. Serum cytokines levels are presented as raw values, while the
statistics was conducted on the logarithmic transformed values. Statistically signif-
icant values are presented in bold.
Patients Controls Statistics
IL-1a (pg/ml) 1.9 ± 0.3 1.1 ± 0.3 t = 2.2, p = 0.03
IL-1b (pg/ml) 6.0 ± 2.8 2.1 ± 0.4 t = 2.7, p = 0.01
IL-2 (pg/ml) 13.6 ± 9.2 4.5 ± 1.3 t = 1.4, p = 0.2
IL-4 (pg/ml) 3.4 ± 0.3 4.6 ± 0.8 t = 1.6, p = 0.1
IL-6 (pg/ml) 2.4 ± 0.6 1.5 ± 0.5 t = 1.8, p = 0.09
IL-8 (pg/ml) 435.4 ± 170.7 71.9 ± 21.8 t = 2.6, p = 0.01
IL-10 (pg/ml) 1.5 ± 0.2 1.9 ± 0.6 t = 0.6, p = 0.5
TNF-a (pg/ml) 62.1 ± 17.7 15.9 ± 5.0 t = 2.0, p = 0.05
INF-c (pg/ml) 1.8 ± 0.2 3.7 ± 1.8 t = 0.7, p = 0.5
VEGF (pg/ml) 123.4 ± 25.3 182.1 ± 32.0 t = 1.7, p = 0.1
EGF (pg/ml) 228.1 ± 27.8 227.3 ± 19.0 t = 0.3, p = 0.8
MCP-1 (pg/ml) 176.1 ± 19.9 156.3 ± 19.0 t = 0.7, p = 0.5
IL-1a mRNA (R) 3.0 ± 0.4 1.7 ± 0.4 t = 2.1, p = 0.04
IL-1b mRNA (R) 1.0 ± 0.1 1.3 ± 0.1 t = 1.7, p = 0.1
IL-6 mRNA (R) 1.5 ± 0.1 1.1 ± 0.1 t = 2.5, p = 0.01
IL-8 mRNA (R) 1.5 ± 0.3 1.0 ± 0.1 t = 1.6, p = 0.1
TNF-a mRNA (R) 1.6 ± 0.1 1.0 ± 0.1 t = 5.4, p < 0.001
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mer set, a validation experiment was performed to demonstrate
that PCR efﬁciencies were within the range of 90–100% and equal
to the efﬁciencies of the reference genes (glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH), beta-actin (ACTB) and beta-2-
microglobulin (B2M)). Each sample was assayed in duplicate and
each target gene (IL-1a, IL-1b, IL-6, IL-8 and TNF-a) was normal-
ized to the gene expression of the three reference genes: GAPDH,
ACTB and B2M. Data were normalized to the geometric mean of
all three reference genes and expressed as Relative Expression Ra-
tio (R).
2.5. Data analysis
Data were analyzed using the Statistical Package for Social Sci-
ences, Version 15.0 (SPSS Inc.). Continuous variables are presented
as mean ± standard error mean. Independent T-test and Chi-square
test were used to compare respectively continuous and categorical
variables between groups. Parametric and non-parametric correla-
tion analyses were used, as appropriate, to test association be-
tween cytokine levels and measures of psychosocial stress,
antipsychotic treatment and current nicotine and cannabis use,
separately in patients and controls. Serum cytokine levels were
normalized for the statistical analyses through logarithmic trans-
formation. Serum cytokines levels are presented as raw values,
while the statistics was conducted on the logarithmic transformed
values.
3. Results
First-episode psychosis patients showed signiﬁcantly higher
serum levels of IL-1a (effect size d = 0.6), IL-1b (d = 0.4), IL-8
(d = 0.6) and TNF-a (d = 0.7) compared with healthy controls. Pa-
tients also had a trend for higher IL-6 serum levels (d = 0.3). No sig-
niﬁcant difference was found between patients and controls for
other serum cytokines (Table 3). We did not ﬁnd any signiﬁcant
correlation between BMI or duration of antipsychotic treatment
and cytokine levels in our patients’ sample (p > 0.05).
Gene expression analyses conducted only in those cytokines
that were different in the serum (IL-1a, IL-1b, IL-6, IL-8 and TNF-
a) revealed signiﬁcantly increased mRNA levels of IL-1a (d = 0.6),
IL-6 (d = 0.7) and TNF-a (d = 1.6) in ﬁrst-episode psychosis patients
when compared with controls. No signiﬁcant difference in gene
expression of IL-1b and IL-8 was found between patients and con-
trols (Table 3). When looking at correlations between serum levels
and mRNA levels of each of the above cytokines, we found a signif-
icant correlation between serum and mRNA levels only for IL-6
(r = 0.553, p = 0.005), and a trend for TNF-a (r = 0.375, p = 0.07);
no signiﬁcant correlation was found between serum and mRNA
levels for the other cytokines (IL-1a, IL-1 b, IL-8).In order to assess the Th1/Th2 cytokines balance between sub-
jects with ﬁrst-episode psychosis and healthy controls, we calcu-
lated the IFNc/IL-4 ratio. We did not ﬁnd a signiﬁcant difference
between the two groups (ﬁrst-episode psychosis vs controls:
0.56 ± 0.06 vs 0.95 ± 0.56, t = 0.7, p = 0.5).3.1. Associations between cytokines levels and psychosocial stress
When looking at the effect of psychosocial stress on cytokine
levels, we found that perceived stress was signiﬁcantly positively
correlated with IL-6 mRNA levels in the control group (r = 0.524,
p = 0.02), and with INF-c serum levels in the patients’ group
(r = 0.486, p = 0.02). We also found that the number of recent
stressful life events was signiﬁcantly positively correlated with
mRNA levels of IL-1b (q = 0.468, p = 0.04) and of TNF-a (q = 0.661,
p = 0.002) in the patients’ group. When looking at the effect of
childhood trauma, we found that healthy controls with childhood
trauma had signiﬁcantly higher mRNA levels of IL-1b compared
with healthy controls without childhood trauma (1.5 ± 0.2 vs
0.9 ± 0.1, t = 2.6, p = 0.02). Similarly, patients with childhood
trauma had signiﬁcantly higher serum levels of TNF-a
(88.7 ± 25.5 vs 7.2 ± 1.0 pg/ml, t = 3.2, p = 0.006) and MCP-1
(216.7 ± 24.9 vs 62.4 ± 9.4 pg/ml, t = 4.3, p = 0.001), but lower ser-
um levels of VEGF (120.8 ± 40.6 vs 165.0 ± 37.7 pg/ml, t = 3.0,
p = 0.008) when compared with patients without childhood trau-
ma. We did not ﬁnd any other signiﬁcant association with other
cytokines (serum or mRNA levels) in either patients’ or control
group.3.2. Associations between cytokines levels and current nicotine or
cannabis use, and employment
We found that serum levels of IL-6 were signiﬁcantly higher in
patients smoking nicotine than in patients who did not smoke
(3.2 ± 1.0 vs 1.0 ± 0.2 pg/ml, t = 2.2, p = 0.04). We also found that
patients smoking cannabis had signiﬁcantly lower serum levels
of IL-2 (3.4 ± 0.7 vs 19.7 ± 14.6 pg/ml, t = 2.1, p = 0.046) and
mRNA levels of IL-1a (1.9 ± 0.4 vs 3.6 ± 0.6, t = 2.1, p = 0.048),
but higher serum levels of MCP-1 (240.3 ± 34.1 vs
137.6 ± 19.1 pg/ml, t = 2.5, p = 0.02) when compared with patients
who did not use cannabis. We did not look at the effect of cannabis
on cytokines levels in healthy controls, since only two of our con-
trols were current cannabis users.
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levels, we found lower mRNA levels of IL-8 in unemployed healthy
controls when compared with employed healthy controls (1.1 ± 0.2
vs 0.7 ± 1.1, t = 2.1, p = 0.048). Patients who were unemployed had
signiﬁcantly higher serum levels of IL-4 (3.6 ± 0.3 vs 2.4 ± 0.2,
t = 2.8, p = 0.01), VEGF (143.6 ± 29.7 vs 58.5 ± 57.8, t = 3.0,
p = 0.007), and EGF (256.4 ± 34.0 vs 123.4 ± 38.4, t = 3.0,
p = 0.008), and lower serum levels of TNF-a (46.1 ± 22.2 vs
123.3 ± 26.5, t = 2.8, p = 0.01).4. Discussion
Our ﬁndings conﬁrm the presence of an inﬂammatory syn-
drome in patients with ﬁrst-episode of psychosis, in the absence
of Th1/Th2 ratio changes.
Interestingly, the ﬁnding of elevated levels of IL-1a, IL-6 and
TNF-a, both in serum and leukocytes gene expression analyses,
provides direct evidence that the immune cells are affected in psy-
chosis, and suggests that the peripheral blood immune cells are the
main source of these cytokines’ elevated levels in the serum. In
contrast, IL-1b and IL-8 were elevated in the serum but not in leu-
kocyte gene expression analyses. This is in agreement with other
studies ﬁnding discrepancies between serum cytokine levels and
cytokine mRNA levels in peripheral blood mononuclear cells
(PBMCs) in other populations (O’Rourke et al., 2006). This differ-
ence may be the result of abnormalities in post-transcriptional reg-
ulation of cytokine expression, leading to a lack of correlation
between transcript levels and protein levels. Moreover, gene
expression may be more easily and rapidly affected than systemic
cytokine levels (Futh et al., 2004), and therefore some differences
between gene expression and serum levels might be related to
the effects of more recent and acute vs chronic activation of the im-
mune system. Alternatively, peripheral blood immune cells are not
the primary source of IL-1b and IL-8 elevated serum levels in these
patients. Indeed, elevated cytokines may derive from cytokine-pro-
ducing cells other than peripheral immune cells, such as intra-he-
patic or adipose tissue-associated cells (O’Rourke et al., 2006). In
our study, we matched our patients and controls for body mass in-
dex, in order to minimize the effect on a potential excess of abdom-
inal adipose tissue on inﬂammatory markers in patients. However,
individuals with identical BMI may have different body composi-
tions with regard to fat and muscle, so we cannot exclude a role
of the adipose tissue or of other lymphoid or non-lymphoid cells
in contributing to the elevated levels of IL-1b and IL-8 found in
our patients. Indeed, increased intra-abdominal fat deposition
has been previously reported in depressed patients who did not
differ for BMI from the comparison healthy control group (Thakore
et al., 1997).
Interestingly, the fact that cytokine expression differs between
the serum and gene expression analyses is also reﬂected in the pat-
tern of associations between serum or leukocytes mRNA cytokines
levels and psychosocial and clinical factors. For example, both ser-
um and gene expression levels of TNF-a are elevated in patients,
but only serum levels correlate with a history of childhood trauma.
This could be again explained by the effects of a long-lasting
chronic activation of the immune system, affecting serum levels.
This notion is consistent with our previous studies ﬁnding an asso-
ciation between a history of childhood trauma and peripheral
inﬂammation in adults (Danese et al., 2007, 2008) as well as chil-
dren (Danese et al., 2010). In contrast, only leukocytes mRNA levels
correlate with a higher number of recent life events, suggesting
that more recent stressors are needed to activate immune cells.
The presence of a pro-inﬂammatory state at the onset of psy-
chosis supports the role of increased inﬂammation in the develop-
ment of psychosis. Indeed, previous studies have shown thatcytokines can affect the synthesis, release and reuptake of neuro-
transmitters as well as inﬂuence neurogenesis (Miller et al.,
2009; Raison and Miller, 2011; Zunszain et al., 2012a,b). In partic-
ular, it has been recently shown that IL-1b exerts a negative effect
on human hippocampal neurogenesis, by activating the kynuren-
ine pathway and subsequently affecting the availability of trypto-
phan and the production of enzymes conducive to neurotoxic
metabolites (Zunszain et al., 2012a). Moreover, preclinical studies
have suggested that pro-inﬂammatory cytokines could directly re-
duce gene transcription of brain-derived neurotrophic factor
(BDNF), further supporting a role of inﬂammation in inﬂuencing
neuroplasticity (Murphy et al., 2000). Interestingly we have re-
cently shown that stressful events can inﬂuence BDNF expression
at the onset of psychosis, and that this association is possibly med-
iated by an inﬂammatory pathway (Mondelli et al., 2011).
Our preliminary ﬁndings support the hypothesis that childhood
trauma and recent stressors contribute to the pro-inﬂammatory
state shown in patients with psychosis. In particular, we found that
childhood trauma and recent stressors increase levels of pro-
inﬂammatory cytokines (TNF-a, IL-1b, INF-c, IL-6) and chemokines
(MCP-1) in either patients or controls, and decrease levels of the
growth factor VEGF in the patients’ group. It is unclear why psy-
chological stress would affect speciﬁc cytokines without appar-
ently affecting others, or why stress would affect different
cytokines in patients and in healthy controls. Indeed, the associa-
tion between childhood trauma and increased levels of TNF-a
has been already recently reported in patients with schizophrenia
(Dennison et al., 2012), while this is the ﬁrst time that childhood
trauma has been found to be associated with increased levels of
MCP-1 and decreased levels of VEGF in patients with psychosis.
MCP-1 is a pro-inﬂammatory chemokine known to play a major
role in the development of cardiovascular disease by promoting
the recruitment of leuokocytes to sites of inﬂammation in the ves-
sel wall (Hansson and Hermansson, 2011). On the other hand,
VEGF is known to have neurotrophic and neuroprotective actions;
low serum VEGF levels have been associated with Alzheimer’s dis-
ease, suggesting their role in a possible neurodegenerative process
(Mateo et al., 2007). Indeed, further studies would need to conﬁrm
these preliminary results and further investigate whether, and
why, psychological stress affects only speciﬁc cytokines.
Our exploratory analyses also showed an association between
current nicotine use and higher IL-6 serum levels but not IL-6
mRNA levels, suggesting that the increased IL-6 production by
the PBMCs cannot be explained by current nicotine use. Cigarette
smoking has been recently shown to have selective effects on ser-
um components of patients with schizophrenia that lead to altered
immune function different from healthy controls (Herberth et al.,
2010). This might partly explain the speciﬁc effect of nicotine use
on IL-6, and the lack of its effect on cytokine levels in our group
of healthy controls. Our ﬁndings of lower IL-1a and IL-2 levels
associated with current cannabis use are not surprising, and are
consistent with previous pre-clinical and clinical studies showing
an anti-inﬂammatory effect of cannabinoids (Klein and Cabral,
2006). Interestingly, we also found that cannabis use was associ-
ated with higher levels of MCP-1 in our patients. One previous
study has demonstrated that a cannabinoid agonist induces a mod-
ulation of speciﬁc chemokines, such as IL-8 and MCP-1, but not of
other chemokines (GRO-a and MIP-1a), indicating a possible spe-
ciﬁc molecular targeting of cannabinoid agonists (Jbilo et al., 1999).
Some limitations of the study need to be acknowledged. First,
for the second aim of the study we conducted multiple correlation
analyses in a relatively small sample of subjects. However, these
should be considered explorative analyses, reporting preliminary
ﬁndings which will need to be validated by future studies.
Secondly, our subjects were non-fasting at time of blood sampling
and the time of blood sampling was random during the day.
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cantly for time of blood sampling, and the blood sample for serum
and mRNA levels was taken at the same time point for each sub-
ject. Moreover, our group of patients was heterogeneous for diag-
nosis, since it included both patients with schizophrenia-like and
affective psychosis. However, a diagnostic heterogeneity is typical
in ﬁrst-episode psychosis, since patients are at the beginning of
their illness, and it represents better what we would expect in a
clinical setting. Last, most patients were taking antipsychotic treat-
ment, although for a short period of time, and this could have con-
founded some of our ﬁndings. However, we did not ﬁnd a
correlation between duration of antipsychotic and cytokine levels
in our patients.
In conclusion, ﬁrst-episode psychosis patients are characterised
by a pro-inﬂammatory state that appears mainly mediated by acti-
vation of the PBMCs; however, other peripheral tissues (such as he-
patic or adipose tissue) also seem to contribute to this
inﬂammatory syndrome. Stressful events, both in childhood and
closer to psychosis onset, appear to contribute to the increased
cytokine production in ﬁrst-episode psychosis.Conﬂict of interest statement
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